TO FORMULATE AND EVALUATE EXTENDED-RELEASE TABLETS OF ETODOLAC (ETD)

***[1]Veena Priya Nair, [2]Ashvani Kumar**

Author (s) affiliations-
*[1]Research Scholar, Institute of Pharmaceutical Sciences & Research, Unnao (UP)
[2]Faculty, Institute of Pharmaceutical Sciences & Research, Unnao (UP)

Corresponding author's details-
***[1]Veena Priya Nair**
*[1]Research Scholar, Institute of Pharmaceutical Sciences & Research, Unnao (UP)
Email id: veenapriyanair11@gmail.com

ABSTRACT

An ideal dosage form is the one which maintain the constant level of drug in the plasma during the entire period of treatment. The aim of the research was to formulate and evaluate extended-release tablets of ETD (etodolac). The etodolac (API) was obtained as gift sample from Bio-Leo analytical Lab, Prashanthinagar and other polymers of analytical grade form the certified suppliers only. The formulated tablets were gone through different evaluation parameters i.e., preformulation studies, weight variation, friability, hardness, disintegration & dissolution, in-vitro drug release, particle size, FT-IR & UV spectroscopy. In results, tablets were found excellent in all the parameters and optimum in the case of drug release. In concludes, that suitable analytical method based on UV-Visible spectrophotometer was developed for the model drug. λ_{max} of 276 was identified for model drug in both 0.1 N HCL and PBS pH 7.0. By performing compatibility studies with DSC no interaction was confirmed. This study suggests that etodolac's extended-release tablets may be used in human beings after estimation of pharmacokinetics profiles in animal/human models.

Key words: *Etodolac, HPMC, sustained release, in-vitro drug release,*